PhRMA’s official statement is now available on its website (though in the USTR’s press release, it finds no voice). On India’s IP regime, keeping up to its banality, it states –
India’s barriers to U.S. trade and investment, including its failure to respect intellectual property rights, continue to harm biopharmaceutical innovators and many other industries across the United States and around the world. While biopharmaceutical innovators saw potentially positive signs from the Indian Government in 2015, translating these positive statements into concrete progress has remained a challenge. PhRMA members welcome USTR’s decision to maintain India on the Priority Watch List and the emphasis the Special 301 Report places on achieving substantive and measurable results. Sustained engagement is essential to promote meaningful reform of India’s patent laws and policies.
In a series of posts, I’ll do a section wise analysis of India’s designation under the Report. I’m particularly keen to see how far PhRMA’s comments to the 2016 Special 301 were taken into account by USTR. Though, its no secret that USTR is the mouth – piece of the Washingtonian lobbyists.